Consumer Medicine Information This leaflet answers some common questions about amoxycillin and clavulanic acid. It does not take the place of talking to your doctor or pharmacist. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you. Amoxycillin and clavulanic acid is used to treat a wide range of infections caused by bacteria. If you have any concerns about taking this medicine, ask your doctor or pharmacist. These infections may affect the chest (bronchitis or pneumonia), bladder (cystitis), sinuses (sinusitis), ears (otitis media) or skin. Clavulanic acid is used to help the amoxycillin work better against certain types of bacteria. Amoxycillin and clavulanic acid works by killing the bacteria that cause these infections. It will not work against infections such as colds or the flu, which are caused by viruses. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason. This medicine is available only with a doctor's prescription. These tablets are not recommended for children weighing less than 40 kg. The combination of amoxicillin and clavulanic acid is used to treat certain infections caused by bacteria, including infections of the ears, lungs, sinus, skin, and urinary tract. Amoxicillin is in a class of medications called penicillin-like antibiotics. Clavulanic acid is in a class of medications called beta-lactamase inhibitors. It works by preventing bacteria from destroying amoxicillin. Antibiotics will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment. The combination of amoxicillin and clavulanic acid comes as a tablet, a chewable tablet, an extended-release (long-acting) tablet, and a suspension (liquid) to take by mouth. The tablets, chewable tablets, and suspension are usually taken at the start of a meal every 8 hours (three times a day) or every 12 hours (twice a day).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets, USP and other antibacterial drugs, amoxicillin and clavulanate potassium tablets, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin and clavulanate potassium tablets, USP are a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: The amoxicillin and clavulanate potassium tablet 250 mg/125 mg and the 250 mg/62.5 mg chewable tablet should NOT be substituted for each other, as they are not interchangeable and the 250 mg/125 mg tablet should not be used in children weighing less than 40 kg. The amoxicillin and clavulanate potassium tablet 250 mg/125 mg and the 250 mg/62.5 mg chewable tablet do not contain the same amount of clavulanic acid. The amoxicillin and clavulanate potassium tablet 250 mg/125 mg contains 125 mg of clavulanic acid whereas the 250 mg/62.5 mg chewable tablet contains 62.5 mg of clavulanic acid. Two amoxicillin and clavulanate potassium tablets 250 mg/125 mg should NOT be substituted for one amoxicillin and clavulanate potassium tablet 500 mg/125 mg. This combination results in an antibiotic with an increased spectrum of action and restored efficacy against amoxicillin-resistant bacteria that produce β-lactamase. Possible side effects include diarrhea, vomiting, nausea, thrush, and skin rash. As with all antimicrobial agents, antibiotic-associated diarrhea due to Clostridium difficile infection—sometimes leading to pseudomembranous colitis—may occur during or after treatment with amoxicillin/clavulanic acid. Rarely, cholestatic jaundice (also referred to as cholestatic hepatitis, a form of liver toxicity) has been associated with amoxicillin/clavulanic acid. The reaction may occur up to several weeks after treatment has stopped, and usually takes weeks to resolve. It is more frequent in men, older people, and those who have taken long courses of treatment; the estimated overall incidence is one in 100,000 exposures. Amoxicillin/clavulanic acid is the International Nonproprietary Name (INN) and co-amoxiclav is the British Approved Name (BAN). Many branded products indicate their strengths as the quantity of amoxicillin.
Β-lactamase−producing strains of Haemophilus influenzae and Moraxella catarrhalis Mild to moderate: 500/125 mg PO q12hr or 250/125 mg PO q8hr for 10 days Severe: 875/125 mg PO q12hr or 500/125 mg PO q8hr or 2000 mg (2 extended-release tabs) PO q12hr for 7-10 days Take with meals to avoid GI upset Take suspension at start of meal to enhance absorption Dysphagia: May substitute 250 mg/5 m L suspension for 500/125 mg tablet; may substitute 200 mg/5 m L or 400 mg/5 m L suspension for 875/125 mg tablet Because of the different amoxicillin-to-clavulanate ratios in the 250-mg tablet (amoxicillin 250 mg, clavulanate125 mg) and the 250-mg chewable tablet (amoxicillin 250 mg, clavulanate 62.5 mg), the 250-mg tablet should not be used if the pediatric patient weighs Hypersensitivity reactions Anaphylaxis Anemia Thrombocytopenia Leukopenia Agranulocytosis Hepatoxicity AST/ALT elevation Pseudomembranous colitis Serum sickness Abdominal discomfort Cholestatic jaundice Flatulence Allergy to cephalosporins, carbapenems Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different Extended release tablets not for use in renal impairment (Cr Cl Amoxicillin binds to penicillin-binding proteins, thus inhibiting final transpeptidation step of peptidoglycan synthesis in bacterial cell walls; addition of clavulanate inhibits beta-lactamase-producing bacteria, allowing amoxicillin extended spectrum of action It is a semisynthetic antibiotic with a broad spectrum of bactericidal activity, covering both gram-negative and gram-positive microorganisms Not effective against Mycoplasma and Legionella spp Peak plasma time: 2 hr (amoxicillin); 1.1 hr (clavulanic acid) Peak concentration: 8-22 mcg/m L (amoxicillin); 0.8-2.6 mcg/m L (clavulanic acid) AUC: 40-80 mcg•hr/m L (amoxicillin); 2-6 mcg•hr/m L (clavulanic acid) The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. Augmentin contains two drugs: amoxicillin and clavulanic acid. Augmentin belongs to the penicillin class of antibiotics. This combination makes Augmentin work against more types of bacteria than antibiotics that contain amoxicillin alone. Augmentin is effective for treating infections caused by many different types of bacteria. These include bacteria that cause: Augmentin is available in a generic form. The generic name of Augmentin is amoxicillin/clavulanate potassium. Generic drugs are often less expensive than the brand-name version.
Consumer information about the medication AMOXICILLIN/CLAVULANIC ACID 875 MG/125 MG - ORAL Augmentin, includes side effects, drug interactions. Wählen Sie eines der folgenden Kapitel aus, um mehr über "AMOXICILLIN/Clavulansäure Heumann 875 mg/125 mg" zu erfahren. Die Informationen zu den Wirkstoffen können im Einzelfall von den Angaben im Beipackzettel mancher Fertigarzneimittel abweichen.